Antibacterial therapy in chronic bronchitis exacerbation: which antimicrobial is optimal?

1. Saint S., Bent S., Vittinghof E., Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analisis. J.A.M.A. 1995; 273; 957-960.

2. Anthonisen N.R., Manfreda J., Warren C.P. et at. Antibiotic therapy in exacerbations of chronic obstructive pulm onary disease. Ann. Intern. Med. 1987; 106: 196-204.

3. Stockley R.A., O'Brien C., Pye A., Hill S.L. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000; 117; 1638-1645.

4. DaganR., Rlugm an K.P., Craig W.A., Baquero F. Evidence to support the rationale that bacterial eradication in the respiratory tract is an important aim of antimicrobial therapy. J. Antimicrob. Chemother. 2001; 47: 129-140.

5. Miravitlles M. Exacerbations of chronic obstructive pulmonary disease when are bacteria important? Eur. Respir. J. 2002; 20 (suppl. 36): 9-19.

6. Anzueto A.R., Schaberg N. Acute exacerbations of chronic bronchitis. Science Press Ltd.; 2003.

7. Blasi F. Atypical pathogens in respiratory tract infections. Eur. Respir. J. 004; 24: 171-181.

8. Bias F. Chlamydia pneumoniae and chronic bronchitis. Thorax 2002; 57: 672-676.

9. Erkan L., Uzun O., Katar D. et al. Infective etiology of acute exacerbation of COPD (AECOPD). Eur. Respir. J. 2004; 24 (suppl. 48): P3200.

10. Balter M .S., LaForge G., Low D.F. et al. Canadien guidelines for the management of acute exacerbations of chronic bronchitis. Can. Respir. J. 2003; 10 (suppl. B): 3B-32B.

11. Adam s S.G, Melo J., Luther М ., Anzueto A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 2000; 117: 1345—1352.

12. Kreis S.R., Herrera N., Golzar N., Fuller H.D. et al. A comparison of moxifloxacin and azithromycin in the treatment of acute exacerbations of chronic bronchitis. JC O M 2000; 7 (12): 33-37.

13. DeAbate C.A., Mathew C.P., Warmer J.H. et al. The safety and efficacy of short course (5-day) moxifloxacin versus asithromycin in the treatmen t of patients with acute exacerbation of chronic bronchitis. Respir. Med. 2000; 94: 1029-1034.

14. Wilson R., Kubin R., Ballin I. et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J. Antimicrob. Chemother. 1999; 44: 501-513.

15. Grassi C., Casali L., Curti E. et al. Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB). J. Chem other. 2002; 14: 597-608.

16. Bauer Т., Landen H. Rapid resolution of symptom s with moxifloxacin therapy in 7223 patients with acute exacerbation of chronic bronchitis. Comparison with prior macrolid treatment. Clin. Drug Invest. 2002; 22: 641-651.

17. Miravitlles М., Murio C., Guerro T. et al. Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest 2003; 123: 784-791.

18. Miravitlles М., Ilor C., Naberan К et al. Effect of various antimicrobial regimens on the clinical course of exacerbations of chronic bronchitis and chronic obstructive pulmonary disease in primary care. Clin. Drug Invest. 2004; 24: 63-72.

19. Landen H., Bauer T. Efficacy, onset of action and tolerability of moxifloxacin in patients with comm unity-acquired pneumonia: results of postmarketing surveillance study. Clin. D rug Invest. 2001;21: 801-811.

20. Wilson R., Allegra L., Huchon G. et al. Short-term and longterm outcom es of moxifloxacin compared to standard antibiotic treatm en t in acute exacerbations of chronic bronchitis. Chest 2004; 125: 953-964.

21. Yakovlev S., Dvorets k y L., Nonikov V. et al. Comparative assessment of moxifloxacin and macrolides in acute exacerbation of chronic bronchitis: clinical efficacy and influence on the longterm prognosis. ECCMID; 2004.